Yingkang Life and Saierxin Biologics Announce Strategic Collaboration to Advance Clinical Development of Regulatory T Cell Therapies

Group Photo of Some Academic or Corporate Experts

Dr. Mingqi Lü, CEO of Shanghai Saierxin Biomedical Technology Co., Ltd. ("NOVABIOTX"), discussed the company's current development projects.Treg Cell TherapyThe project was shared.

Reporting and Discussion Site

Taking this opportunity to jointly advance the clinical treatment of regulatory T cells, and in accordance with the cooperation principles of "voluntary equality, complementary advantages, and mutual benefit," NOVABIOTX and YK HEALTHCARE have signed a strategic cooperation agreement.

This strategic cooperation willBased on NOVABIOTX's research achievements in regulatory T cells, and combining YK HEALTHCARE's clinical research capabilities and resource aggregation abilities, both parties will engage in in-depth cooperation in areas such as the clinical application of regulatory T cell therapeutic products.It is hoped that through the cooperation of both parties, the commercial development and industrial transformation of similar products can be accelerated, jointly promoting the transformation of R&D results, expediting new drug launches, and continuously meeting patient needs.

NOVABIOTX was founded in 2022, focusing on the development of treatments.Neurodegenerative diseases, autoimmune diseases, and metabolic diseasesMulti-Modal Treg Cell Therapy. After years of extensive research, we have discovered that Treg can effectively suppress the proliferation and function of pro-inflammatory cells in autoimmune diseases from multiple aspects, thereby achieving therapeutic effects. NOVABIOTX adheres to the core mission of "addressing unmet clinical needs" and upholds the core values of "patient-centricity, integrity, pragmatism, and perseverance," leading the industrial development of Treg.

YK HEALTHCARE is a leading healthcare industry under Haier, focusing on three major fields: life sciences, medical devices, and medical services. It has two listed companies: Haier Biomedical (688139.SH) and YK LIFE (300143.SZ).

From focusing on the quality of life to the quality of life itself, we always put user needs at the center, providing global users with high-end equipment for biosecurity and life sciences, medical devices addressing clinical pain points, and digital-intelligent health scenario solutions serving "city-hospital-district-family".

Currently, YK Healthcare has established 8 major healthcare innovation industrial parks and 6 regional medical service ecosystems. Its products and services cover more than 160 countries and regions globally, and it maintains long-term cooperative relationships with over 50 international organizations. Meanwhile, YK Healthcare has been listed for three consecutive years as the only "large healthcare industry ecosystem brand" on the "Top 500 Most Valuable Brands in China." In the 2023 Ecological Brand Certification list, it ranked in the "Breakthrough" quadrant.

Positioned in the large health industry ecosystem driven by technology and intelligence, YK HEALTHCARE is always committed to innovating through technology and service to tirelessly work for everyone's lifelong health.